JP2023554081A5 - - Google Patents

Info

Publication number
JP2023554081A5
JP2023554081A5 JP2023537034A JP2023537034A JP2023554081A5 JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5 JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023537034 A JP2023537034 A JP 2023537034A JP 2023554081 A5 JP2023554081 A5 JP 2023554081A5
Authority
JP
Japan
Prior art keywords
variant
variable region
chain variable
nucleotide sequence
sequence seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554081A (ja
Filing date
Publication date
Priority claimed from CN202011485792.8A external-priority patent/CN114634575B/zh
Application filed filed Critical
Publication of JP2023554081A publication Critical patent/JP2023554081A/ja
Publication of JP2023554081A5 publication Critical patent/JP2023554081A5/ja
Pending legal-status Critical Current

Links

JP2023537034A 2020-12-16 2021-12-15 補体抑制剤の開発及び応用 Pending JP2023554081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011485792.8 2020-12-16
CN202011485792.8A CN114634575B (zh) 2020-12-16 2020-12-16 一种补体抑制剂的开发和应用
PCT/CN2021/138447 WO2022127834A1 (zh) 2020-12-16 2021-12-15 一种补体抑制剂的开发和应用

Publications (2)

Publication Number Publication Date
JP2023554081A JP2023554081A (ja) 2023-12-26
JP2023554081A5 true JP2023554081A5 (cg-RX-API-DMAC7.html) 2024-04-15

Family

ID=81944764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537034A Pending JP2023554081A (ja) 2020-12-16 2021-12-15 補体抑制剤の開発及び応用

Country Status (9)

Country Link
US (1) US20240067751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4265641A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554081A (cg-RX-API-DMAC7.html)
KR (1) KR20230118941A (cg-RX-API-DMAC7.html)
CN (4) CN120173119B (cg-RX-API-DMAC7.html)
AU (1) AU2021398697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202507A1 (cg-RX-API-DMAC7.html)
IL (1) IL303794A (cg-RX-API-DMAC7.html)
WO (1) WO2022127834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7690612B2 (ja) * 2021-06-08 2025-06-10 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 抗masp-2抗体及びその使用
JP2024524440A (ja) * 2021-06-30 2024-07-05 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規抗masp-2抗体
WO2023103789A1 (zh) * 2021-12-10 2023-06-15 舒泰神(北京)生物制药股份有限公司 特异性识别masp2的抗体及其应用
EP4643878A2 (en) * 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
EP3150635A3 (en) * 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP2019533423A (ja) * 2016-07-06 2019-11-21 シャンハイ ファーマエクスプローラー カンパニー,リミティド BLyS抗体及びその製造方法と応用
EP3836965A4 (en) * 2018-06-22 2022-04-20 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用

Similar Documents

Publication Publication Date Title
IL303794A (en) Development and application of an inhibitory complement
US20250304717A1 (en) Camptothecin derivative and ligand-drug conjugate
JP2023509196A5 (cg-RX-API-DMAC7.html)
CN106211782B (zh) 抗体-fynomer缀合物
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2019503167A5 (cg-RX-API-DMAC7.html)
JP2018527908A5 (cg-RX-API-DMAC7.html)
JP2006505277A5 (cg-RX-API-DMAC7.html)
JP2019522050A5 (cg-RX-API-DMAC7.html)
JP2021500391A5 (cg-RX-API-DMAC7.html)
JP2020511936A5 (cg-RX-API-DMAC7.html)
JP2011207882A5 (cg-RX-API-DMAC7.html)
JP2011505146A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2016503295A5 (cg-RX-API-DMAC7.html)
JP2012070737A5 (cg-RX-API-DMAC7.html)
AU2010248365A1 (en) Anti-AXL antibody
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2011518857A5 (cg-RX-API-DMAC7.html)
JP2022521850A5 (cg-RX-API-DMAC7.html)
CA3214808A1 (en) Thienopyrrole compounds
JP2026048732A5 (cg-RX-API-DMAC7.html)
JP2008542321A5 (cg-RX-API-DMAC7.html)
JP2011505371A5 (cg-RX-API-DMAC7.html)
JP2026514033A (ja) 抗cdh6抗体-薬物コンジュゲート及びその使用